These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33404019)

  • 1. Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease.
    Verma P; Srivastava A; Srikanth CV; Bajaj A
    Biomater Sci; 2021 Mar; 9(5):1481-1502. PubMed ID: 33404019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.
    Le Berre C; Loy L; Lönnfors S; Avedano L; Piovani D
    World J Gastroenterol; 2020 Aug; 26(29):4343-4355. PubMed ID: 32848338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review.
    Ardekani ZM; Lorenzo-Leal AL; Bach H
    Nanomedicine (Lond); 2024 Jan; 19(2):163-179. PubMed ID: 38284393
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of chitosan as nano carrier in the treatment of inflammatory bowel disease.
    Liu X; Dong Y; Wang C; Guo Z
    Int J Biol Macromol; 2024 Oct; 278(Pt 4):134899. PubMed ID: 39187100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease-An Overview.
    Lopes SA; Roque-Borda CA; Duarte JL; Di Filippo LD; Borges Cardoso VM; Pavan FR; Chorilli M; Meneguin AB
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.
    Liu P; Gao C; Chen H; Vong CT; Wu X; Tang X; Wang S; Wang Y
    Acta Pharm Sin B; 2021 Sep; 11(9):2798-2818. PubMed ID: 34589398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy.
    Jacob EM; Borah A; Pillai SC; Kumar DS
    Nanomaterials (Basel); 2020 Dec; 10(12):. PubMed ID: 33316984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review.
    Jakubczyk D; Leszczyńska K; Górska S
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32630805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis.
    Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H
    Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment.
    Coqueiro AY; Raizel R; Bonvini A; Tirapegui J; Rogero MM
    Int J Food Sci Nutr; 2019 Feb; 70(1):20-29. PubMed ID: 29804478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.
    Soroosh A; Koutsioumpa M; Pothoulakis C; Iliopoulos D
    Am J Physiol Gastrointest Liver Physiol; 2018 Feb; 314(2):G256-G262. PubMed ID: 29146677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nanogel based oral gene delivery system targeting SUMOylation machinery to combat gut inflammation.
    Yavvari PS; Verma P; Mustfa SA; Pal S; Kumar S; Awasthi AK; Ahuja V; Srikanth CV; Srivastava A; Bajaj A
    Nanoscale; 2019 Mar; 11(11):4970-4986. PubMed ID: 30839018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
    Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
    Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
    BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.